Treatment for Alzheimer's failed to slow mental decline in a widely anticipated study, ending hope that researchers at Eli Lilly had finally found a drug that does more to help those suffering from the fatal, mind-robbing disease. The pharmaceutical company's shares plunged 14 percent Wednesday before markets opened. The drug, solanezumab, missed the study's main goal when patients taking it did not experience a statistically significant slowing of cognitive decline — which involves a person's ability to remember things — compared to those taking a placebo or fake drug.
Juno Therapeutics halts midstage clinical trial after patient death
Juno Therapeutics Inc. JUNO, -28.88% shares were halted in pre-market trade Wednesday after the company said one patient in its cancer trial had died and one was "not expected to recover." The two patients both experienced brain trauma earlier in the week during a phase 2 trial for a leukemia treatment, the company said. Two patients died in early July in the same clinical trial, but the company was allowed to resume the trial without the chemotherapy drug fludarabine, which Juno believed caused the deaths in combination with the company's JCAR015 drug. This week, Juno put the trial on clinical hold
Comment: Bernie routinely hits on Pharma. Meanwhile yield in LLY is 2.66%
Americans pay the highest prices in the world for prescription drugs. The result: 1 in 5 patients cannot afford to fill their prescriptions.— Bernie Sanders (@SenSanders) November 22, 2016